Form 4: Ocular Therapeutix CSO Executes Tax-Related Stock Sale

Chief Scientific Officer Jeffrey S. Heier sold 3,018 shares of Ocular Therapeutix common stock to satisfy tax obligations.

Summary

• Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc., sold 3,018 shares of common stock.
• The transaction occurred on May 26, 2026, at a weighted average price of $8.20 per share.
• The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units.
• Following the transaction, the reporting person retains ownership of 320,350 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was a mandatory tax-related sale rather than a discretionary market move.

Positives

• The sale was non-discretionary and executed pursuant to a pre-existing Rule 10b5-1 trading plan.
• The transaction was specifically for tax compliance rather than a signal of negative sentiment regarding company performance.

Negatives

• The transaction represents a reduction in the insider's direct equity stake in the company.

Risks

• Reliance on Rule 10b5-1 plans does not eliminate market risk for the reporting person.
• Fluctuations in the company's stock price impact the value of remaining holdings.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this filing.

Management Comments

• The sales do not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that this filing is a routine administrative disclosure common in the biotechnology sector, where executives frequently utilize Rule 10b5-1 plans to manage tax liabilities associated with equity compensation.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans for tax-to-cover transactions is standard practice for executive officers at publicly traded biotech firms like Ocular Therapeutix.
• The volume of shares sold is immaterial relative to the total outstanding shares of the company.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and tax-related.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

OCUL, Ocular Therapeutix, Insider Trading, Form 4, Chief Scientific Officer, Tax Withholding